Evaluation of safety of insulin degludec on undergoing total-colonoscopy using continuous glucose monitoring

Evaluation of safety of insulin degludec on undergoing total-colonoscopy using continuous glucose monitoring - Safety of degludec on undergoing total-colonoscopy using CGM

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012265

Enrollment

Registered

2013-11-11

Start date

2013-11-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus colon cancer

Interventions

In admission, CGM was attached from the previous day to the following day of TCS. Patients had been fasting for 24 hours after the supper (6 pm) on the previous day. At breakfast and lunch on the day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes mellitus treated with insulin degludec

Exclusion criteria

Exclusion criteria: 1) severe renal dysfunction (serum creatinine level over 2.0 mg/dL) 2) judged to be unsuitable for participation for medical reasons

Design outcomes

Primary

Measure	Time frame
Primary endpoints were to evaluate the frequency of hypoglycemia (below 70 mg/dl), Hypoglycemic Index, mean glucose level (MEAN) and standard deviation (SD) in daytime fasting duration (between 8 am and 6 pm on the day of TCS) (F duration).	—

Countries

Japan

Contacts

Public ContactTakeisi Soichi

Ichinomiyanishi Hospital Department of Endocrinology and Diabetes

souichi19811225@yahoo.co.jp0586-48-0077

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026